Show simple item record

dc.contributor.authorLutfi, Forat
dc.contributor.authorWu, Long
dc.contributor.authorSunshine, Sarah
dc.contributor.authorCao, Xuefang
dc.date.accessioned2021-10-15T18:35:49Z
dc.date.available2021-10-15T18:35:49Z
dc.date.issued2021-09-22
dc.identifier.urihttp://hdl.handle.net/10713/16855
dc.description.abstractImmune checkpoint inhibitor therapies and allogeneic hematopoietic cell transplant (alloHCT) represent two distinct modalities that offer a chance for long-term cure in a diverse array of malignancies and have experienced many breakthroughs in recent years. Herein, we review the CD27-CD70 co-stimulatory pathway and its therapeutic potential in 1) combination with checkpoint inhibitor and other immune therapies and 2) its potential ability to serve as a novel approach in graft-versus-host disease (GVHD) prevention. We further review recent advances in the understanding of GVHD as a complex immune phenomenon between donor and host immune systems, particularly in the early stages with mixed chimerism, and potential novel therapeutic approaches to prevent the development of GVHD.en_US
dc.description.urihttps://doi.org/10.3389/fimmu.2021.715909en_US
dc.language.isoenen_US
dc.publisherFrontiers Media S.A.en_US
dc.relation.ispartofFrontiers in Immunology Open Accessen_US
dc.rightsCopyright © 2021 Lutfi, Wu, Sunshine and Cao.en_US
dc.subjectCD27en_US
dc.subjectCD70en_US
dc.subjectallogeneic hematopoietic cell transplant (alloHCT)en_US
dc.subjectgraft-versus-host disease (GVHD)en_US
dc.subjectimmunotherapyen_US
dc.titleTargeting the CD27-CD70 Pathway to Improve Outcomes in Both Checkpoint Immunotherapy and Allogeneic Hematopoietic Cell Transplantationen_US
dc.typeArticleen_US
dc.identifier.doi10.3389/fimmu.2021.715909
dc.identifier.pmid34630390
dc.source.volume12
dc.source.beginpage715909
dc.source.endpage
dc.source.countrySwitzerland


This item appears in the following Collection(s)

Show simple item record